| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology and Neurosciences, UMDNJ–New Jersey Medical School, Newark.
Address correspondence and reprint requests to Dr. Andrew R. Pachner, Department of Neurology and Neurosciences, UMDNJ–New Jersey Medical School, 185 S. Orange Ave., Newark, NJ 07103; e-mail: Pachner{at}umdnj.edu
A reliable screening assay for anti-interferon beta (IFNß) antibodies is needed for patients with multiple sclerosis (MS) receiving IFNß therapy. The performance of a new ELISA method, the capture ELISA (cELISA), was assessed by comparing it to a standard IFNß ELISA in correlating with neutralizing antibodies measurement in 453 sera from patients with MS. The cELISA outperformed the standard ELISA, and may be a suitable screening assay for anti-IFNß antibodies in IFNß-treated patients with MS.
Received April 25, 2003. Accepted in final form July 26, 2003.
This article has been cited by other articles:
|
|
 |
|
  C Gneiss, M Brugger, A Millonig, A Fogdell-Hahn, D Rudzki, J Hillert, T Berger, M Reindl, and F Deisenhammer Comparative study of four different assays for the detection of binding antibodies against interferon-{beta} Multiple Sclerosis, July 1, 2008; 14(6): 830 - 836. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, and A. Bertolotto Predictive markers for response to interferon therapy in patients with multiple sclerosis Neurology, March 25, 2008; 70(13_Part_2): 1119 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Wiesemann, M. Deb, C. Trebst, B. Hemmer, M. Stangel, and A. Windhagen Effects of interferon-{beta} on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-{beta} treatment in patients with multiple sclerosis Multiple Sclerosis, March 1, 2008; 14(2): 166 - 176. [Abstract] [PDF]
|
|
|
|
|
|
R. Farrell, R. Kapoor, S. Leary, P. Rudge, A. Thompson, D. Miller, and G. Giovannoni Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta Multiple Sclerosis, March 1, 2008; 14(2): 212 - 218. [Abstract] [PDF]
|
|
|
|
|
|
A.R. Pachner Neutralizing anti-IFN{beta} antibodies: clarity and confusion Multiple Sclerosis, November 1, 2007; 13(9): 1081 - 1082. [PDF]
|
|
|
|
|
|
F Gilli, F Hoffmann, A Sala, F Marnetto, M Caldano, P Valentino, L Kappos, A Bertolotto, and R L. Lindberg Qualitative and quantitative analysis of antibody response against IFN{beta} in patients with multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 738 - 746. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Chadha, B. Weinstock-Guttman, R. Zivadinov, K. Bhasi, J. Muhitch, J. Feichter, M. Tamano-Blanco, N. Abdelrahman, J. Ambrus Sr, F. Munschauer, et al. Interferon Inhibitory Activity in Patients With Multiple Sclerosis Arch Neurol, November 1, 2006; 63(11): 1579 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Pachner, K. Narayan, and E. Pak Multiplex analysis of expression of three IFN{beta}-induced genes in antibody-positive MS patients Neurology, February 14, 2006; 66(3): 444 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Ross, K M Clemmesen, P S Sorensen, N Koch-Henriksen, and K Bendtzen Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis Multiple Sclerosis, February 1, 2006; 12(1): 39 - 46. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
